(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 5. Hormone inducible dominant-negative Sox9 construct. (A) Schematic
representation of Sox9, Sox9
C and Sox9
C-GR fusion constructs.
Sox9 lacking the transactivation domain (Sox9
C) is fused to the
ligand-binding domain of human glucocorticoid receptor (hGR). The HMG box is
highlighted in blue, and the putative transactivation domain is underlined in
red. (B) Western blot analysis of Sox9
C-GR protein in extracts from
Sox9
C-GR-injected embryos collected at different stages. The fusion
protein is expressed at similar levels at all stages (stage 10-20). This Sox9
antibody directed against the N-terminal domain of Sox9 does not allow
detection of endogenous Sox9 protein (control, uninjected embryo). Tubulin is
presented as a loading control.